Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)
Publication date
2020-07
Authors
Verheijen, R. B.
Swart, E L
Beijnen, J H
Schellens, J H M
Huitema, Alwin D.R.
Steeghs, Neeltje
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
In the original publication of the article, the second author name has been misspelled.
Keywords
Taverne, Pharmacology (medical), Oncology, Cancer Research, Toxicology, Pharmacology, Published Erratum
Citation
Verheijen, R B, Swart, E L, Beijnen, J H, Schellens, J H M, Huitema, A D R & Steeghs, N 2020, 'Correction to : Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)', Cancer Chemotherapy and Pharmacology, vol. 86, no. 1, 163, pp. 1. https://doi.org/10.1007/s00280-020-04090-4